Align Technology, Inc. (ALGN) is set to release first-quarter 2024 results on Apr 24 after the closing bell.The company posted adjusted earnings per share (EPS) of $2.42 in the last reported quarter, which topped the Zacks Consensus Estimate by 11%. Align Technology beat earnings estimates in three of the trailing four quarters and missed in one, the average negative surprise being 5.82%.Let’s look at how things have shaped up before this announcement.Factors at PlayClear Aligner BusinessSimilar to the last ...

Align Technology‘s (ALGN) shares have surged 20.5% year to date compared with the industry’s growth of 6.2%. The Medical sector has gained 3% in the said time frame. The company has a market capitalization of $24.80 billion.This Zacks Rank #2 (Buy) stock is well-positioned to drive the digital revolution in the dental industry with Invisalign clear aligners, Itero Scanners and the Align digital platform. Its earnings are expected to grow 14.2% in the next year.Will the Upside Continue?The consensus estimate ...

Align Technologies (ALGN) recently announced that the Invisalign Palatal Expander system is now commercially available in Australia and New Zealand. The system has been included in the Australian Register of Therapeutic Goods and the New Zealand Web-Assisted Notification of Devices Database and covers broad patient applicability, including growing children, teens and adults (with surgery or other techniques).The newest development is expected to significantly boost ALGN’s Clear Aligner segment. Following it ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Align Technology (ALGN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Align Technology is a member of our Medical group, which includes 1054 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the str ...

Core Insights - Align Technology is well-positioned in the malocclusion market, which affects approximately 60% to 75% of the global population, translating to around 500 million individuals [1] - The company has achieved significant milestones, including treating 17 million Invisalign patients, with 4.7 million being teens, and a total of 809,000 Clear Aligner shipments for teens, marking an 8% increase from 2022 [2] - Align Technology has launched innovative products, including the Doctor Subscription Program and received FDA clearance for the Invisalign Palatal Expander System, expanding its product offerings [3] Market Opportunities - The malocclusion market presents a substantial growth opportunity for Align Technology, particularly in increasing its share of orthodontic case starts among teens and expanding digital orthodontics for adults [2] - The company is also set to roll out the ClinCheck smile video, enhancing its digital treatment planning capabilities with AI technology [3] Challenges - The ongoing economic uncertainty and industry-wide staffing shortages are negatively impacting Align Technology's growth, compounded by rising raw material and labor costs due to global inflation [4] - The military conflict between Russia and Ukraine poses additional challenges, with potential supply issues and macroeconomic uncertainties expected to affect operations [5] - Foreign exchange fluctuations have significantly impacted revenues, with 44% of the company's revenues coming from international markets, leading to a $12.8 million adverse effect on clear aligner revenues in the fourth quarter [6][7]

It has been about a month since the last earnings report for Align Technology (ALGN) . Shares have added about 10.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Align Technology due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Align Technology Tops Q4 Earnings, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________ FORM 10-K ________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fil ...

Core Viewpoint - Merit Medical (MMSI) is currently viewed as a better value opportunity compared to Align Technology (ALGN) based on various financial metrics and analyst outlooks [1][3]. Group 1: Zacks Rank and Analyst Outlook - MMSI has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while ALGN has a Zacks Rank of 3 (Hold) [1]. - The improving analyst outlook for MMSI suggests a more favorable investment environment compared to ALGN [3]. Group 2: Valuation Metrics - MMSI has a forward P/E ratio of 23.87, significantly lower than ALGN's forward P/E of 31.20, indicating that MMSI may be undervalued [2]. - The PEG ratio for MMSI is 2.12, while ALGN's PEG ratio is 2.49, suggesting that MMSI offers better value relative to its expected earnings growth [2]. - MMSI's P/B ratio stands at 3.72, compared to ALGN's P/B of 6.22, further supporting the notion that MMSI is a more attractive investment [2]. Group 3: Value Grades - Based on the analysis, MMSI has a Value grade of B, while ALGN has a Value grade of C, reinforcing the conclusion that MMSI is the superior value option at this time [3].

Group 1 - Align Technology's stock initially rose by 15% after reporting Q4 2023 financial results, but later surrendered gains to be up less than 1% [1] - The company generated net revenue of $957 million in Q4 2023, a nearly 7% year-over-year increase, exceeding management's guidance of $920 million to $940 million [2] - Management provided guidance for modest top-line growth and improvement in operating margin for 2024, leading to upgrades from Wall Street analysts [2] Group 2 - Align Technology achieved an 11.5% net profit margin in 2023, indicating strong profitability [3] - The company plans to invest $100 million in 2024 to support manufacturing and has introduced a new, faster, and smaller version of the iTero scanner to attract more doctors [3] - In 2023, Align Technology repurchased 1 million shares and has $650 million remaining in share repurchase authorization [3]

Core Viewpoint - Align Technology, Inc. reported strong fourth-quarter fiscal 2023 results with adjusted earnings per share (EPS) of $2.42, reflecting a 39.9% increase year over year, surpassing the Zacks Consensus Estimate by 11% [1] Financial Performance - Fourth-quarter revenues increased by 6.1% year over year to $956.7 million, exceeding the Zacks Consensus Estimate by 3% [2] - Full-year revenues for 2023 reached $3.86 billion, up 3.4% from 2022, also surpassing the Zacks Consensus Estimate by 0.8% [2] Segment Analysis - Clear Aligner segment revenues rose by 6.9% year over year to $781.9 million, driven by higher average selling prices and non-case revenues, despite lower volumes [3] - Imaging Systems & CAD/CAM Services revenues increased by 2.9% to $174.8 million in the quarter [3] Margins and Expenses - Gross profit for the fourth quarter was $669.5 million, an 8.4% increase year over year, with a gross margin expansion of 146 basis points to 70.0% [4] - Operating income increased by 48.9% to $184.9 million, with an operating margin expansion of 556 basis points to 19.3% [4] Cash Flow and Financial Position - At the end of the fourth quarter, cash and cash equivalents were $937.4 million, down from $1.23 billion at the end of the third quarter [5] - Cumulative net cash provided by operating activities was $785.8 million, up from $738.9 million in the previous quarter [5] Future Guidance - For 2024, Align Technology anticipates mid-single-digit revenue growth compared to 2023, with a Zacks Consensus Estimate of $4.06 billion [6] - The company plans to invest approximately $100 million in capital expenditures for building improvements and manufacturing capacity [6] Strategic Developments - The company gained FDA clearance for the Invisalign Palatal Expander System and launched the new iTero Lumina intraoral scanner, enhancing practice efficiency [7] - Continued focus on international expansion, patient demand, and orthodontist utilization to maintain leadership in digital orthodontics and dentistry [7]